Keira Smith: Hi. I'm Keira Smith from Oncology Data Advisor. I'm here today with Allison Imahiyerobo. Allison Imahiyerobo: Hi Keira, my name is Alli Imahiyerobo. I'm a nurse practitioner, and I practice at Hematology Oncology Physicians of Englewood in New Jersey. I focus on both benign and malignant hematology. Keira Smith: What are some of the most challenging aspects of treating patients with immune thrombocytopenia, or ITP? Allison Imahiyerobo: I think that it's really twofold. The first cha...

Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x109/L with no known cause (Rodeghiero et al, 2009). The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children (Terrell et al, 2010). Research has shown that the burden of ITP is significant. A survey of more than 1,300 patients across 13 countries showed 36% reported a high impact on emotional well-being...

Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x 109/L with no known cause. In this excerpt of the transcript from her nursing continuing professional development (NCPD)–approved activity, Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care, Allison Miller Imahiyerobo, APN, an advanced practice nurse at the Hematology and Oncology Physicians of Englewood, discusses the pathogenesis of ITP, eme...

Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...